度普利尤单抗与曲罗芦单抗治疗特应性皮炎的真实世界倾向评分调整比较
基于荷兰BioDay登记的前瞻性队列研究,纳入750例未使用过生物制剂/JAK抑制剂的AD患者(度普利尤单抗643例,曲罗芦单抗107例),采用IPTW平衡组间特征。结果显示度普利尤单抗在瘙痒NRS、达到EASI≤7和NRS≤4的概率及52周药物存活率方面优于曲罗芦单抗,但应答者继续治疗时EASI和瘙痒差异较小。
要点
- 度普利尤单抗组52周EASI≤7和NRS≤4的达标率风险差分别为34.7%和40.2%。
- 52周药物存活率度普利尤单抗92.6% vs 曲罗芦单抗70.6%。
- 眼表疾病发生率两组相似(HR 1.0,95%CI 0.6-1.6,p=0.94)。
核心结论
- 在真实世界比较中,度普利尤单抗的有效性优于曲罗芦单抗。
- 在继续治疗的应答者中,EASI和瘙痒NRS差异较小;但考虑治疗目标(EASI≤7、NRS≤4)和停药率后差异更明显。
研究设计与样本
- 共750例患者(度普利尤单抗643例,曲罗芦单抗107例),采用逆概率治疗加权(IPTW)平衡组间特征。
- 随访至52周,评估EASI、周均瘙痒NRS、治疗达标阈值(EASI≤7;NRS≤4,停药者视为无应答)及药物存活率,每次访视评估不良事件。
主要发现
- 度普利尤单抗组EASI评分低于曲罗芦单抗组,但差异未持续具有统计学意义(p=0.10)。
- 度普利尤单抗组NRS瘙痒评分在所有访视点均显著更低(p<0.0001),但平均差异未超过2分的临床相关阈值。
- 度普利尤单抗组达到EASI≤7和NRS≤4的概率更高(均p<0.0001),52周风险差分别为34.7%和40.2%。
- 52周药物存活率度普利尤单抗92.6% vs 曲罗芦单抗70.6%。
- 眼表疾病发生率两组相似(HR 1.0,95%CI 0.6-1.6,p=0.94),导致停药者度普利尤单抗23例(3.4/100 PY),曲罗芦单抗5例(5.4/100 PY)。
关键数值与推荐
- 治疗达标阈值:EASI≤7;周均瘙痒NRS≤4,停药患者视为无应答。
- 52周达到EASI≤7的风险差为34.7%,达到NRS≤4的风险差为40.2%。
- 52周药物存活率:度普利尤单抗92.6%,曲罗芦单抗70.6%。
- 眼表疾病HR 1.0(95%CI 0.6-1.6,p=0.94)。
临床怎么用
- 对于未使用过生物制剂的AD患者,度普利尤单抗在真实世界中显示出更高的治疗达标率和药物存活率。
- 选择度普利尤单抗或曲罗芦单抗时,可结合治疗目标(EASI≤7、NRS≤4)和停药风险进行个体化决策。
- 眼表疾病发生率两组相似,但仍需在治疗过程中监测眼部不良反应。
局限性
- 非随机对照研究,尽管采用IPTW调整,仍可能存在未测量混杂。
- 曲罗芦单抗组样本量(107例)明显小于度普利尤单抗组(643例)。
- 随访时间为52周,长期有效性及安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dupilumab and tralokinumab for atopic dermatitis (AD) target the type 2 axis through different mechanisms of action, which may lead to variation in effectiveness and safety. Head-to-head trials, however, are lacking. OBJECTIVES: To compare the real-world effectiveness and safety of dupilumab and tralokinumab in AD. METHODS: This prospective cohort study enrolled biologic-/Janus kinase inhibitor-naïve AD patients (≥12 years) from the BioDay registry who initiated dupilumab or tralokinumab between November 2021 and September 2024. Visits were scheduled at baseline, 4 weeks and every 3 months up to 52 weeks. Effectiveness outcomes included Eczema Area and Severity Index (EASI), weekly mean pruritus Numeric Rating Scale (NRS), treat-to-target thresholds (EASI ≤ 7; NRS-pruritus ≤ 4, with patients discontinuing treatment considered non-responders) and drug survival. Adverse events (AEs) were assessed at each visit. Inverse probability of treatment weighting (IPTW) was used to balance treatment groups. RESULTS: In total, 750 patients were included (643 dupilumab; 107 tralokinumab). After IPTW, baseline characteristics were well balanced. During follow-up, dupilumab patients had lower EASI scores than tralokinumab patients, although differences were not consistently statistically significant (p = 0.10). NRS-pruritus scores were significantly lower with dupilumab at all visits (p < 0.0001), mean differences did not exceed the 2-point clinical relevance threshold. The probability of achieving EASI ≤ 7 and NRS-pruritus ≤ 4 was higher with dupilumab (both p < 0.0001), with risk differences of 34.7% and 40.2% at 52 weeks, respectively. After 52 weeks, dupilumab drug survival was 92.6% vs. 70.6% for tralokinumab. Ocular surface disease incidence was similar (HR 1.0, 95% CI 0.6-1.6, p = 0.94) between treatments, leading to discontinuation of dupilumab in n = 23 (3.4/100 PY) and tralokinumab in n = 5 (5.4/100 PY). CONCLUSIONS: In this real-world comparison, dupilumab provided superior effectiveness compared with tralokinumab. In responders continuing treatment, EASI and NRS-pruritus differences were small. More substantial differences were observed when treatment targets EASI ≤ 7 and NRS-pruritus ≤ 4, and discontinuation rates were taken into account. Comparing dupilumab and tralokinumab treatment for atopic dermatitis Atopic dermatitis, also known as eczema, is a common long‐term skin disease that can cause intense itching and redness of the skin. Recently, several new treatments became available for people with moderate‐to‐severe eczema. These therapies include dupilumab and tralokinumab, which are given by injection and work by targeting specific parts of the immune system. Although both treatments are effective and safe, choosing between them can be challenging, as very few studies have directly compared these therapies. In this study, we used data from the Dutch BioDay registry, which follows patients with eczema who are treated with these new medicines as part of their usual care. We compared the effectiveness and safety of dupilumab and tralokinumab via assessment of the improvement of skin lesions, using the Eczema Area and Severity Index (EASI), patient‐reported itch and evaluation of side effects. Patients were followed for 1 year. In total, 750 patients were included in the study: 643 were treated with dupilumab and 107 with tralokinumab. Most patients experienced improvement of their eczema, with lower mean EASI and itch scores over the study period for both treatments. Improvements were slightly greater with dupilumab than with tralokinumab, and more patients stopped tralokinumab treatment because their eczema symptoms did not improve enough. The overall occurrence of side effects did not differ between the two treatments. Irritation of the eyes was the most frequently reported side effect. This real‐life comparative study may help patients and clinicians weigh the benefits and risks of dupilumab and tralokinumab treatment and support informed treatment decision‐making.
引用
- van der Gang LF, Zuithoff NPA, Haeck IM, et al. Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay. J Eur Acad Dermatol Venereol. 2026. PMID: 41969170. doi:10.1111/jdv.70442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。